Endrolin

Quick links to important sections

Endrolin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Endrolin

What is Endrolin?

Endrolin is a hormonal medication belonging to a class of drugs known as gonadotropin-releasing hormone (GnRH) agonists. Its active ingredient, leuprorelin acetate, is a synthetic analog of the naturally occurring hormone produced in the brain.

Mechanism of Action

The medication works by interacting with the pituitary gland to regulate the production of certain hormones. Initially, the administration of Endrolin causes a temporary increase in the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). However, with continuous use, the medication desensitizes the pituitary gland. This leads to a significant reduction in the levels of these hormones, which in turn suppresses the production of testosterone in males and estrogen in females.

Therapeutic Use

By lowering the levels of sex hormones to what is often described as a prepubertal or castrate level, Endrolin helps manage conditions that are sensitive to these hormones. This therapeutic approach is used in various clinical scenarios:

  • Oncology: It is used in the treatment of advanced prostate cancer, where reducing testosterone levels can slow or stop the growth of hormone-dependent tumor cells.
  • Gynecology: It is utilized to manage conditions such as endometriosis by suppressing the estrogen that fuels the growth of endometrial tissue outside the uterus. It is also used to reduce the size of uterine fibroids before surgical intervention.
  • Pediatrics: In cases of central precocious puberty, it is used to temporarily delay the onset of early puberty by suppressing the premature release of reproductive hormones.

What side effects are possible with Endrolin?

Possible Side Effects and Safety Information

The safety profile of Endrolin (leuprorelin acetate) is primarily characterized by the adverse reactions resulting from its mechanism of inducing hormonal quiescence (low sex hormone levels). These effects are categorized by frequency and the body system affected, based on regulatory documentation.


Adverse Reaction Classifications

Very Common Adverse Reactions officially listed include hot flashes (flushes) and various injection site reactions such as pain, erythema, and bruising. Common Reactions include effects on multiple systems, such as nausea (Gastrointestinal Disorders), headache (Nervous System Disorders), depression (Psychiatric Disorders), and fatigue or asthenia (General Disorders).

Serious Adverse Reactions documented in regulatory sources include rare events such as anaphylactic reactions and, in patients with pre-existing conditions, pituitary apoplexy. Reports of seizures and, in men, an increased risk of serious cardiovascular events have also been noted.


Time-Related and Population-Specific Safety Patterns

The safety profile includes specific patterns tied to the duration of exposure. At the start of treatment (initial weeks), a transient increase in sex hormone levels, known as a 'flare effect,' may cause a temporary worsening of symptoms. Conversely, long-term exposure to Endrolin is associated with a decrease in bone mineral density in both men and women.

Safety Constraints for Endrolin explicitly state that it is contraindicated in individuals with known hypersensitivity to GnRH, GnRH agonists, or excipients. Furthermore, due to the risk of fetal harm, it is contraindicated in women who are or may become pregnant and in nursing mothers.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory prescribing information for Endrolin (leuprorelin acetate) consistently indicates that clinical experience with acute overdose is limited. Consequently, there is often an absence of specific clinical symptoms uniquely documented for acute excess exposure in the general population. The overall profile emphasizes mandated emergency response and supportive management.

Emergency Actions Required

If an overdose is suspected or confirmed, the patient must seek immediate medical attention. This urgent action is mandated because no specific antidote is known for leuprorelin acetate. Management of the condition is focused entirely on providing symptomatic and supportive treatment and requires careful observation of the patient by medical personnel, which may include laboratory monitoring of hormone levels.

Documented Risks and Considerations

The primary concern documented in regulatory sources is the risk of an exaggeration of the known pharmacological effects. This can lead to profound hormonal suppression that is more severe or prolonged than the intended therapeutic effect. Furthermore, official labeling highlights a population-specific toxicity consideration: certain liquid formulations contain benzyl alcohol, and excessive exposure to these specific products carries a documented risk of toxicity, such as Gasping Syndrome in neonates and infants. All circumstances involving suspected over-administration require the patient to contact emergency medical services immediately.

Therapeutic Uses of Endrolin

What Endrolin Treats: Main Uses and Benefits

Endrolin (leuprorelin) is commonly used to help with a range of conditions. It is applied across domains where additional symptomatic support is needed for patients experiencing distressing symptoms. Therapeutic areas for the active ingredient include its relevance for conditions such as advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.


Managing Symptomatic Discomfort and Functional Strain

Endrolin is applied across domains where additional symptomatic support is needed, often when symptoms related to physical discomfort or irritative states intensify. It assists with managing groups of symptoms that can appear suddenly, which contributes to easing the overall symptom load. The medication may be utilized in clinical settings where multiple symptoms occur together, creating a noticeable interference with daily functioning.

“Endrolin may assist with maintaining functional stability and may offer supportive relief when symptoms become momentarily overwhelming.”

The medication is generally considered relevant in contexts marked by increased physiological tension, particularly across conditions involving episodic or fluctuating manifestations. It may help patients cope more steadily with symptom fluctuations, and may support the patient during difficult episodes by easing distress.

Quick Fact: Supports Easing Physical Discomfort

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Endrolin — Official Regulatory Information

Regulatory documentation establishes specific patient population rules for Endrolin (leuprorelin acetate), defining who is permitted to use the medicine and who is absolutely prohibited.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adult males for prostate cancer; premenopausal adult females for endometriosis and uterine fibroids. Pediatric patients (children ge 1 year) for Central Precocious Puberty (CPP).
Populations for whom use is not recommended Breastfeeding women (due to insufficient data). Children younger than 2 years for CPP treatment.
Populations for whom use is contraindicated Patients with known hypersensitivity to GnRH, GnRH agonists, or excipients. Women who are or may become pregnant. Women with undiagnosed abnormal uterine bleeding (for female-specific indications).
Age-related eligibility rules Use is established in adults and in children for the approved CPP indication.

Eligibility-Related Restrictions

Official labeling requires close monitoring for specific populations where use is allowed, including men with pre-existing risk factors for cardiovascular disease and patients with a history of seizures or CNS anomalies. The safety and efficacy of Endrolin have not been established in children outside of the CPP indication or in patients with renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Endrolin (leuprorelin acetate) is defined by a low risk of metabolic interactions and specific pharmacodynamic cautions, as documented by regulatory authorities.

Pharmacodynamic Interaction Cautions

The drug’s function as a Gonadotropin-Releasing Hormone (GnRH) agonist introduces two primary pharmacodynamic interaction constraints:

  • Hormonal Agents: Co-administration with other medicinal products that influence the hypothalamic-pituitary-gonadal (HPG) axis may modify the overall level of hormonal suppression achieved.
  • Cardiovascular Risk: Androgen Deprivation Therapy (ADT) carries a documented potential to prolong the corrected QT interval of the heart. This creates an additive risk when Endrolin is co-administered with other medicinal products known to prolong the QT interval, such as specific antiarrhythmic or antidepressant drugs.

Metabolic and Substance Interactions

Due to its peptide structure, Endrolin is primarily degraded by peptidases, not the common Cytochrome P450 (CYP) enzyme system. Regulatory documents state that clinically significant CYP-mediated pharmacokinetic interactions are not expected.

Furthermore, official regulatory labels do not document specific interaction-related restrictions or prohibitions concerning:

  • Food or mealtimes
  • Alcohol consumption
  • Herbal products or supplements

No mandatory dose timing or separation requirements are documented for co-administered oral or injectable medicinal products. There are no formal drug-drug combinations classified as contraindicated solely due to interaction risk.

Mechanism of Action

Central Pituitary Receptor Downregulation

The mechanism of action for Endrolin (Leuprorelin acetate) begins centrally at the anterior pituitary gland, where the active ingredient functions as a synthetic nonapeptide agonist on the Gonadotropin-Releasing Hormone Receptors ( GnRH-R). This agonist action, resulting from continuous non-pulsatile exposure, forces the GnRH-Rs into a state of downregulation and desensitization. This crucial cellular process functionally renders the pituitary gland temporarily unresponsive to endogenous GnRH signaling.


Sequential HPG Axis Suppression

Pituitary desensitization initiates a systemic cascade across the Hypothalamic-Pituitary-Gonadal ( HPG) Axis. By inhibiting the release of the key regulatory hormones, Luteinizing Hormone ( LH) and Follicle-Stimulating Hormone ( FSH), the mechanism removes the hormonal drive required for gonadal steroidogenesis. The resulting physiological effect is a profound and sustained reduction in circulating levels of testosterone and estrogen, leading to a state of sustained suppression of sex hormone production.


Mechanistic Biphasic Constraint

The mechanism is biphasic due to initial agonist activity. Upon first administration, the hyperstimulation of the GnRH-R causes a transient, temporary surge—known as the Flare Effect—in LH, FSH, and subsequently, sex hormones, before the downregulation process takes full effect. This biphasic constraint means the state of hormone suppression is not achieved instantly but requires two to four weeks for the downregulation phase to be completed.

Dosage and Administration Information

How to Use Endrolin: Official Administration Guidelines

Endrolin (leuprorelin acetate) is administered following established regimens which dictate the dose, frequency, and method of injection. The administration of both the solution and depot suspension forms must be performed by a healthcare professional.


Administration Scope Official Instruction Detail
Route of Administration The medicine is given as a Subcutaneous (SC) or Intramuscular (IM) injection, depending on the specific formulation. Intra-arterial or intravenous routes are to be strictly avoided.
Dosing Schedule The selection of dose is non-additive and must align with the target dosing interval. Schedules range from the 1 mg SC daily solution to multi-month depot injections (e.g., 7.5 mg every 4 weeks, 22.5 mg every 12 weeks, or 45 mg every 24 weeks).
Preparation Requirements Lyophilized depot formulations must be reconstituted with the supplied diluent immediately prior to use. The resulting suspension should appear milky and must be administered promptly, as these preparations lack a preservative.
Age-Group Rules Pediatric dosing for Central Precocious Puberty (CPP) is weight-based, with the dose adjusted if adequate hormonal suppression is not achieved. No specific dose adjustment is explicitly required for the elderly.
Course Duration For conditions such as prostate cancer, treatment is typically continuous and long-term. For benign conditions like endometriosis or uterine fibroids, treatment is limited to a finite course (e.g., up to three to six months).
Special Procedural Conditions Injection sites (e.g., gluteal area, thigh, shoulder) should be rotated periodically. For the treatment of endometriosis, administration is typically initiated during the first 5 days of the menstrual cycle.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Initial Trials

Research has primarily focused on the pharmacokinetic profile of the substance, exploring how it is absorbed, distributed, metabolized, and excreted. Initial studies investigated activity related to inflammation and cellular signaling.

Specifically, early-stage clinical studies examined key biological markers for any measured change in a small group of participants. These initial findings are considered preliminary, and the focus was on establishing tolerance and basic biological activity rather than conclusive therapeutic findings.

Research Pathways Investigated

Researchers investigated the substance's interaction with specific biological pathways. Further research has investigated whether the substance was correlated with a measured change in symptom parameters, though these findings are not yet conclusive. Research has explored changes in disease progression over time in limited cohorts.

It is important to note that describing an interaction in a laboratory setting does not equate to a guaranteed clinical finding.

Combination Therapy Studies

Research has also explored the use of the substance in conjunction with established treatment protocols, examining how the substance interacts with commonly prescribed medications. For example, research has explored measured endpoints when the substance was administered alongside other treatments, when compared to the existing standard of care alone. Findings have been mixed, and more large-scale, controlled studies are needed to draw clear conclusions regarding any potential complementary investigation.

Adverse Event Profile Examination

The body of research has also included assessments of the substance's measured adverse event profile, with researchers evaluating the frequency and nature of reported events.

Key Studies & References A single-dose, randomized, open-labeled, parallel-group study comparing the pharmacokinetics, pharmacodynamics and safety of leuprolide acetate microspheres 3.75 mg and Enantone® 3.75 mg in healthy male subjects

Frequently Asked Questions (FAQ)

Common questions about Endrolin (FAQ)


Q: Why is Endrolin prescribed for two different conditions?

Endrolin is prescribed for different diseases, such as prostate cancer and endometriosis, because of its single core mechanism. The drug is designed to suppress the production of sex hormones (testosterone in men and estrogen in women). Since both of these diseases are hormone-dependent, the suppression of the relevant hormone is the therapeutic goal for both indications, according to official documents.


Q: How quickly can someone expect to feel the effects of Endrolin?

Regulatory documents state that the body's hormonal suppression phase is typically achieved within two to four weeks after starting treatment. This is the period required for the drug's mechanism to take full effect. However, the time it takes for an individual to notice symptom relief can vary based on the treated condition.


Q: Does Endrolin cause changes in appetite or weight?

Official drug information indicates that weight gain is a possible, though uncommon, adverse effect. Specific changes in appetite are not consistently listed among the most common adverse reactions. Communication with the healthcare provider about any such changes is recommended.


Q: What happens if a dose of Endrolin is forgotten?

Official guidance states that contact with the healthcare provider is necessary immediately if a scheduled injection is missed. Endrolin must be given at specific, continuous intervals to maintain the drug's therapeutic effect. The healthcare provider can provide guidance on the necessary steps to ensure the treatment schedule is maintained.


Q: Is Endrolin suitable for people with pre-existing heart conditions?

Official safety information notes that treatment with GnRH agonists like Endrolin is associated with an increased risk of serious cardiovascular events in men. Patients who have pre-existing heart conditions or relevant risk factors must be closely monitored. These factors are generally considered when assessing eligibility for treatment.


Q: Can Endrolin affect mood or sleep patterns?

Official documents list several adverse reactions affecting mental state and general well-being. This includes reports of depression, mood changes, and trouble sleeping (insomnia). Patients are advised to inform their healthcare team of any changes.


Q: How does Endrolin interact with common over-the-counter pain relievers?

Endrolin is primarily degraded by enzymes other than the Cytochrome P450 system, meaning clinically significant interactions with many drugs, including common OTC pain relievers, are not expected. Consultation with a healthcare provider regarding all co-administered medicines is necessary to assess potential risks.


Q: Is Endrolin treatment covered by research studies for its long-term impact?

Yes, the body of research and post-marketing surveillance includes data on the long-term effects of Endrolin. This information specifically reports that extended use is associated with a risk of decreased bone mineral density in both male and female patients.


Q: Is Endrolin available as a generic medicine?

The active ingredient in Endrolin is leuprorelin acetate. This active ingredient is available in various formulations from different manufacturers, including both brand-name and generic long-acting products, according to the records of regulatory agencies.


Q: Can Endrolin be taken with a chronic medicine for high blood pressure?

Endrolin carries a risk of interaction with certain medicines that prolong the QT interval of the heart. Official safety guidelines recommend review of all chronic prescription drugs with a healthcare professional to assess overall safety and check for this interaction.


Q: Does Endrolin work differently in men compared to women?

The drug's core mechanism is the same for all patients: it suppresses the pituitary gland to reduce hormonal activity. The resulting physiological effect, however, is different, leading to a sustained reduction of testosterone in men and estrogen in pre-menopausal women.


Q: What is the longest period Endrolin has been studied for continuous use?

The duration of continuous use varies by indication; for conditions like cancer, treatment is often continuous and long-term. In clinical studies for Central Precocious Puberty (CPP), continuous treatment has been reported to exceed three to four years.


Q: If the medicine is stopped, do the original symptoms return immediately?

Official documents indicate that the effect of hormonal suppression from the drug is reversible upon discontinuation. The time it takes for the body's natural HPG axis to fully recover varies, but the return of original symptoms is generally anticipated once the hormonal suppression ends.


Q: Are there specific times of day that Endrolin is usually recommended to be taken?

For most indications, no general time of day (such as morning or evening) is specified for the injection. However, regulatory documents state that for women being treated for endometriosis, administration is typically initiated during the first five days of the menstrual cycle.


Q: Does Endrolin affect lab test results?

Official adverse event reports mention several laboratory abnormalities that have been reported with treatment. These include changes in blood cell counts and increases in certain blood chemistry levels, such as triglyceride and cholesterol.


Q: Is Endrolin typically started at a low amount and then increased?

For adult indications, treatment usually follows a fixed, scheduled dose. However, for pediatric patients being treated for Central Precocious Puberty, the dose is weight-based and may be adjusted upward if blood tests show that adequate hormonal suppression has not been achieved.


Q: Does Endrolin cause sensitivity to the sun?

Yes, official post-marketing surveillance reports mention that photosensitivity reactions have been observed with this class of drug. This means there is an increased sensitivity of the skin to sunlight during treatment.


Q: Does Endrolin have any known effects on fertility?

The drug's mechanism is designed to suppress the hormones necessary for reproduction, and official information states that treatment may impair fertility in men. Official guidance for women of childbearing potential recommends the use of non-hormonal contraception methods during treatment.


Q: How often do people taking Endrolin need follow-up appointments?

The necessary frequency of follow-up and monitoring tests is determined by the healthcare team based on the specific condition and the dosing schedule. This ensures that hormone levels remain suppressed and that the patient's general health and organ function are monitored.


Q: Is it mandatory to have specific tests before starting Endrolin?

Yes. Before starting treatment, patients typically undergo blood tests to check for necessary baseline levels, such as blood cells and liver function. Regulatory guidance states that for women of childbearing age, a pregnancy test is necessary to rule out pregnancy prior to initiation.


Q: Can Endrolin be crushed or split?

No. Endrolin is an injectable medicine administered either as a solution or a suspension by a healthcare professional. It is not available in oral forms like tablets or capsules, and therefore cannot be crushed, split, or used orally.


Q: Why are people with liver problems sometimes unable to use Endrolin?

Official drug information notes that the safety and effectiveness of Endrolin have not been established in patients with renal or hepatic (liver) impairment. Furthermore, liver toxicity is a possible adverse reaction, and monitoring liver function is often done with blood tests throughout the course of treatment.


Q: Does Endrolin interact with contraceptives?

Women using Endrolin are advised in official warnings to use non-hormonal methods of birth control. Official warnings recommend the use of non-hormonal methods of birth control for women using Endrolin because the drug poses a risk of harm to a fetus, and hormonal contraceptives could interfere with the intended hormonal suppression.

How should Endrolin be stored and disposed of?

Storage and Disposal Instructions for Endrolin

Official regulatory documents specify mandatory conditions for storing Endrolin (leuprorelin acetate) to maintain its chemical stability and efficacy.


Required Storage Conditions

  • Temperature: The product must be stored at room temperature, specifically below 77^circF (25^circC).
  • Light Protection: It must be protected from light and remain in its original carton until use.
  • Freezing: Endrolin must not be frozen.
  • Stability: The reconstituted suspension for injection must be used immediately or discarded if not used within two hours.

Disposal and Safety

  • Child Safety: The medicine, needles, and syringes must be kept out of the sight and reach of children.
  • Sharps Disposal: Used needles and syringes must be placed immediately into a designated, puncture-resistant sharps container.
  • General Disposal: The disposal of unused medicine and other components must be conducted according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Endrolin found in:

A-Z Index: